I
Ismael Samudio
Researcher at Pontifical Xavierian University
Publications - 90
Citations - 8511
Ismael Samudio is an academic researcher from Pontifical Xavierian University. The author has contributed to research in topics: Apoptosis & Leukemia. The author has an hindex of 44, co-authored 87 publications receiving 7982 citations. Previous affiliations of Ismael Samudio include Centre for Drug Research and Development & Texas A&M University System.
Papers
More filters
Journal ArticleDOI
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
Marina Konopleva,Rooha Contractor,Twee Tsao,Ismael Samudio,Peter P. Ruvolo,Peter P. Ruvolo,Shinichi Kitada,Xingming Deng,Dayong Zhai,Yue Xi Shi,Thomas Sneed,Monique Verhaegen,Maria S. Soengas,Vivian Ruvolo,Teresa McQueen,Wendy D. Schober,Julie C. Watt,Tilahun Jiffar,Xiaoyang Ling,Frank C. Marini,David Harris,Martin Dietrich,Zeev Estrov,James A. McCubrey,W. Stratford May,John C. Reed,Michael Andreeff +26 more
TL;DR: ABT-737 effectively kills acute myeloid leukemia blast, progenitor, and stem cells without affecting normal hematopoietic cells, suggesting that ABT- 737 could be a highly effective antileukemia agent when the mechanisms of resistance identified here are considered.
Journal ArticleDOI
Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction
Ismael Samudio,Romain Harmancey,Michael Fiegl,Hagop M. Kantarjian,Marina Konopleva,Borys Korchin,Kumar Kaluarachchi,William G. Bornmann,Seshagiri Duvvuri,Heinrich Taegtmeyer,Michael Andreeff +10 more
TL;DR: It is demonstrated that pharmacologic inhibition of FAO with etomoxir or ranolazine inhibited proliferation and sensitized human leukemia cells to apoptosis induction by ABT-737, and evidence suggesting that FAO regulates the activity of Bak-dependent mitochondrial permeability transition is generated.
Journal ArticleDOI
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
Zhihong Zeng,Yue Xi Shi,Ismael Samudio,Rui Yu Wang,Xiaoyang Ling,Olga Frolova,Mark J. Levis,Joshua B. Rubin,Robert R. Negrin,Elihu H. Estey,Sergej Konoplev,Michael Andreeff,Marina Konopleva +12 more
TL;DR: It is demonstrated that in vivo studies demonstrated that AMD3465 induced mobilization of AML cells and progenitor cells into circulation and enhanced antileukemic effects of chemotherapy and sorafenib, resulting in markedly reduced leukemia burden and prolonged survival of the animals.
Journal ArticleDOI
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.
Kensuke Kojima,Marina Konopleva,Marina Konopleva,Ismael Samudio,Ismael Samudio,Masato Shikami,Masato Shikami,Maria Cabreira-Hansen,Maria Cabreira-Hansen,Teresa McQueen,Teresa McQueen,Vivian Ruvolo,Vivian Ruvolo,Twee Tsao,Twee Tsao,Zhihong Zeng,Zhihong Zeng,Lyubomir T. Vassilev,Lyubomir T. Vassilev,Michael Andreeff,Michael Andreeff +20 more
TL;DR: No induction of apoptosis was observed in AML samples harboring mutant p53, and p53 activation by targeting the p53-MDM2 interaction might offer a novel therapeutic strategy for AML that retain wild-type p53.
Journal ArticleDOI
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML
Zhihong Zeng,Dos D. Sarbassov,Dos D. Sarbassov,Ismael Samudio,Karen W.L. Yee,Mark F. Munsell,C. Ellen Jackson,Francis J. Giles,David M. Sabatini,David M. Sabatini,Michael Andreeff,Marina Konopleva +11 more
TL;DR: This study provides the first evidence that rapamycin derivatives inhibit AKT signaling in primary AML cells both in vitro and in vivo, and supports the therapeutic potential of mTOR inhibition strategies in leukemias.